Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2867346 | 0.75 | ADRB3 (0.40) | SMN1; SMN2CYP3A4CYP2C19MAPT | |
| SCHEMBL2864239 | 0.74 | USP30 (0.46) | ALDH1A1KMT2ACYP3A4CYP2C19HTT | |
| SCHEMBL13049842 | 0.74 | L3MBTL1 (0.69) | ALDH1A1KMT2ASMN1; SMN2MEN1LMNA | |
| SCHEMBL5960104 | 0.74 | ALDH1A1 (1.00) | ALDH1A1KMT2ASMN1; SMN2CYP2C19L3MBTL1 | |
| SCHEMBL2861732 | 0.72 | EPHX2 (0.62) | ALDH1A1SMN1; SMN2CYP3A4CYP2C19HTT | |
| SCHEMBL2857688 | 0.72 | MEN1 (0.66) | ALDH1A1KMT2ASMN1; SMN2MEN1LMNA | |
| SCHEMBL2867569 | 0.71 | MEN1 (0.54) | ALDH1A1KMT2AMEN1LMNAGAA | |
| SCHEMBL2853527 | 0.71 | ALDH1A1 (0.63) | ALDH1A1KMT2ASMN1; SMN2HTTMAPT | |
| SCHEMBL2856032 | 0.70 | HPGD (0.51) | ALDH1A1KMT2AMEN1LMNAL3MBTL1 | |
| SCHEMBL10779664 | 0.70 | KMT2A (0.47) | ALDH1A1KMT2ASMN1; SMN2HTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2253328-A1 | Cycloalkyl inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNN3, KCNQ5 | ALDH1A1 4075/4885KMT2A 1396/4885SMN1; SMN2 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.